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Abstract
The non-competitive NMDA receptor antagonist MK-801 elicits a behavioural syndrome in rodents
characterized by hyperlocomotion and stereotypies, which is antagonized by antipsychotic drugs. NMDA
receptor antagonists increase prefrontal cortex (PFC) activity in rodents, as assessed by electro-
physiological and neurochemical measures. The increase in glutamate outﬂow induced by systemic
MK-801 administration in the medial PFC (mPFC) is prevented by the local administration of clozapine
(Clz). In the present study, we examine whether a PFC lesion alters the behavioural syndrome induced by
MK-801 in rats and the Clz-induced antagonism of MK-801 actions. We evaluated the hyperlocomotion,
stereotypies and other behavioural changes induced by MK-801 in the open ﬁeld and the eﬀect of
electrolytic lesions of the mPFC, and of cortical transection on the behavioural syndrome induced by
MK-801 and its reversal by Clz. MK-801 (0.1–0.2 mg/kg i.p.) reduced rearings but only the higher dose
induced hyperlocomotion. At this dose, MK-801 also increased disorganized movements, head weavings,
and induced ataxia signs. An electrolytic lesion of the mPFC markedly reduced the number of rearings
pre-treatment but caused a very slight attenuation of MK-801-induced hyperlocomotion. Cortical tran-
section did not signiﬁcantly alter MK-801 eﬀects. Clz administration (1 mg/kg s.c.) signiﬁcantly
attenuated hyperlocomotion, head weavings and ataxia signs induced by MK-801 but did not prevent the
decrease in rearings. The eﬀect of Clz was essentially unaﬀected by electrolytic lesions of the mPFC. These
results show that MK-801-induced motor syndrome and its reversal by Clz are mostly independent on
PFC integrity.
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Introduction
Non-competitive NMDA receptor antagonists, such as
phencyclidine or MK-801 induce a potent behavioural
syndrome (hyperactivity, ataxia signs, stereotypies),
as well as cognitive and sensory deﬁcits in exper-
imental animals that resemble human schizophrenia
symptoms (Javitt and Zukin, 1991 ; Krystal et al., 1994 ;
Malhotra et al., 1997; Newcomer et al., 1999). NMDA
receptor antagonists also aggravate this array of
symptoms in schizophrenia patients (Krystal et al.,
2003). In common with schizophrenia symptoms, the
behavioural eﬀects of NMDA receptor antagonists are
sensitive to treatment with antipsychotic drugs (Geyer
et al., 2001 ; Krystal et al., 2003).
Despite the widespread use of NMDA receptor
antagonists as pharmacological models of schizo-
phrenia, their neurobiological basis of action is still
poorly understood. Neuroimaging studies indicate
that a sub-anaesthetic dose of ketamine increases the
activity of the prefrontal cortex (PFC) in human volun-
teers (Breier et al., 1997). In experimental animals,
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NMDA receptor antagonists such as MK-801
or phencyclidine have been shown to increase the
neuronal activity in the medial prefrontal cortex
(mPFC) (Jackson et al., 2004 ; Kargieman et al., 2007;
Suzuki et al., 2002) and glutamate release in this area
(Adams andMoghaddam, 2001; Lo´pez-Gil et al., 2007;
Lorrain et al., 2003 ; Moghaddam et al., 1997). These
drugs also increase the release of monoamines in
the mPFC, such as dopamine (Mathe´ et al., 1999;
Moghaddam and Adams, 1998 ; Schmidt and Fadayel,
1996), serotonin (Adams and Moghaddam, 2001;
Amargo´s-Bosch et al., 2006 ; Lo´pez-Gil et al., 2007;
Martin et al., 1998 ; Millan et al., 1999) and acetyl-
choline (Nelson et al., 2002). Given the prominent
role of monoamines in PFC function (Robbins, 2000)
these changes might partly mediate MK-801- or
phencyclidine-induced behaviours.
The PFC is involved in a large number of higher
brain functions such as working memory, action
planning and behavioural inhibition (Fuster, 1997;
Miller and Cohen, 2001), which are altered in schizo-
phrenia patients. Macroscopic and microscopic
pathological changes have been reported in the PFC
of schizophrenia patients, e.g. reduction layer thick-
ness, increased packing density of pyramidal neurons
and reduced number and function of chandelier
GABAergic neurons (Harrison, 1999 ; Lewis et al.,
2005). The PFC exerts a top-down control of many
other cortical and subcortical areas in the brain
including motor and limbic areas with which the
PFC is reciprocally connected in most instances
(Miller and Cohen, 2001). Pyramidal neurons in the
PFC receive a large array of inputs from sensory
and associative cortical areas, as well as from the
thalamus, the hippocampus and other subcortical
structures. In turn, axons of pyramidal neurons
project to and modulate neuronal activity in these
areas (Fuster, 1997 ; Groenewegen and Uylings, 2000;
Miller and Cohen, 2001). Since NMDA receptor
antagonists increase the activity of PFC neurons
(Homayoun and Moghaddam, 2007a; Jackson et al.,
2004 ; Kargieman et al., 2007; Suzuki et al., 2002), it
may be possible that the behavioural syndrome
evoked by these agents results from a PFC-induced
activation of cortical and subcortical motor areas
secondary to the increase of PFC activity. In the
present study we further characterized the behav-
ioural syndrome produced by MK-801 and examined
whether a lesion of the mPFC can prevent or atten-
uate some of the behavioural signs induced by
MK-801. Moreover, we also examined whether the
clozapine (Clz) reversal of MK-801 eﬀects depends
on mPFC integrity.
Methods
Animals
Male Wistar rats (250–300 g) were obtained from
IIBCE Bioterio (Montevideo, Uruguay). All rats were
maintained in groups of six in clear plastic cages
(50r30r20 cm) at 22¡2 xC on a constant light–
dark cycle (07 :00–19 :00 hours) and had unlimited
access to food and water. Animal care followed the
European Union regulations (O.J. of E.C. L358/1
18/12/1986) and experiments were conducted ac-
cording to local ethical guidelines (IIBCE, Montevideo,
Uruguay).
Drugs and treatments
(+)-MK-801 [dizocilpine (5R,10S)-(1)-5-methyl-10,11-
dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine hy-
drogen maleate)] was from Sigma RBI (Natick, MA,
USA), Clz was from Tocris (Bristol, UK) and ketamine
(50 mg/ml) and xylazine (20 mg/ml) were from
Konsol Ko¨ning SA Laboratory (BA, Argentina).
MK-801 was dissolved in saline and Clz was dissolved
in a minimal volume of 0.1 M HCl, and diluted with
saline (pH adjusted to 5–6 with NaOH). Aliquots were
prepared and stored at x20 xC. Clz vehicle was also
stored atx20 xC.
Drugs were injected intraperitoneally (i.p.) or
subcutaneously (s.c.) and control groups received the
corresponding saline or vehicle injection. MK-801 was
injected i.p. at 0.1 and 0.2 mg/kg, Clz was injected at
1 mg/kg s.c. In experiments involving a single drug
injection, drugs were administered 30 min before
starting the behavioural testing. In experiments as-
sessing the Clz reversal of MK-801 actions, the anti-
psychotic was administered 5 min before MK-801 (see
Figure 1). Drugs were administered at 1 ml/kg. All
experiments were performed between 08:00 and
13:00 hours.
Behavioural experiments
Rats were brought in their home cages to the exper-
imental room, identiﬁed and weighed 1 d before
Exploratory phase
Habituation phase
–35 –30
Start behavioural testVehicle or Clz
injection
MK-801 or saline
injection
Electrolytic lesion,
cortical transection
or sham condition
7 d Time
(min)
5 15100
Figure 1. Schematic representation of the experimental
protocol.
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the behavioural experiments to allow acclimation to
the test environment. The experimental room was
under controlled temperature (22¡2 xC) and the be-
havioural testing was conducted using the open-ﬁeld
(OF) paradigm, as previously described (Lagos et al.,
1998 ; Scorza et al., 1996). The same OF was used in all
experiments. Brieﬂy, the OF apparatus consists of a
square Plexiglas cage (60r60r40 cm) with red walls
to minimize outside light and noise. The OF is equip-
ped with an optical system to measure animal activity,
consisting of eight photocell beams on each side of
the arena, forming a grid of 64 equally sized squares.
The OF is connected to a computer running motor
behavioural monitor software which automatically
records the number of beam crosses (total locomotor
activity). Experiments were carried out under dim
light.
On the day of experiment, the animals were
administered either drug or vehicle. After treatment,
rats were individually placed in the centre of the
OF and were left to move freely for 15 min. Before
placing each individual rat in the OF, the OF ﬂoor
was covered with a thin layer of fresh gravel. After
behavioural monitoring, the gravel was removed
and the ﬂoor was cleaned with an alcohol/water
solution and left to dry before testing the next rat.
All animals were naive to the OF. Two diﬀerent
periods were distinguished and computed, a ﬁrst
5-min period corresponding to the exploratory
phase of the unfamiliar OF and a further 10-min
period corresponding to the habituation phase (see
Figure 1). We measured the overall locomotor
activity and other behavioural signs such as rearings,
head weavings and head shakes. Head weavings
were deﬁned as a lateral side-to-side movement
of the head with no net locomotion (Spanos and
Yamamoto, 1989). Likewise, we scored the number
of ataxia signs, including behaviours such as oc-
casional fallings during horizontal displacement or
by loss of balance while rearing. We also scored the
intensity of the disorganization of locomotor activity
(e.g. movements not guided by normal exploratory
behaviour) using a 0–3 point scale (0=absent,
1=unclear-slight, 2=clearly present, 3=intense)
(Tricklebank et al., 1984). Behaviour was scored
during the actual experiments by an experimenter
blind to the treatment. Experiments were videotaped
for further conﬁrmation of initial visual scores. Rats
were used only once and experimental groups were
balanced to keep constant the four treatments in the
same number of rats in each experimental session.
Ratings were carried out simultaneously by two
experimenters.
PFC lesions
Electrolytic lesions in the mPFC were performed as
follows. Rats were anaesthetized with a mixture of
ketamine (90 mg/kg i.p.) and xylazine (5 mg/kg i.p.)
and positioned in a stereotaxic instrument (David
Kopf Instruments, Tujunga, CA, USA). A bipolar
nichrome electrode (120 mm diameter, insulated ex-
cept at the tip) was stereotaxically descended at two
diﬀerent AP coordinates (AP +3.2 and +3.7 mm),
L ¡0.8 (bilateral). Descents were made at x3, x4
andx5.4 mm (DV). Constant current (1 mA, 10 s) was
injected at these sites, using a Grass S4 stimulator
connected to a Grass constant current stimulus iso-
lation unit. In total, 12 lesion points were made for
each rat (six per hemisphere). Coordinates were taken
from bregma and duramater (Paxinos and Watson,
2005). Sham rats underwent the same surgical pro-
cedure but electrode descents were not performed to
avoid physical damage of the mPFC. After recovering
from anaesthesia, rats were returned to their home
cages and behavioural experiments were conducted
7 d after the lesion.
To further examine the involvement of PFC on
the locomotor eﬀect of MK-801, a group of rats was
subjected to cortical transection, as described in
Dı´az-Mataix et al. (2005) with some modiﬁcations.
Brieﬂy, rats were deeply anaesthetized with ketamine
(90 mg/kg i.p.) and xylazine (5 mg/kg i.p.) and placed
in a stereotaxic apparatus. Cortical transection was
stereotaxically performed using a ﬁne metal needle
(0.6 mm diameter), which was positioned at AP+3.2,
DVx6.0, L+0.4 and moved stereotaxically to L¡4.5.
To avoid damaging the sinus and cutting prefrontal
aﬀerents to midbrain, transection of right hemisphere
was conducted at AP +3.2, DV x6.2, L from x0.4 to
x4.5 with an angle of 20x. Figure 2(a–d) shows the
schematic location of PFC lesions and examples of the
actual lesions. Rats with incomplete lesions or when
these fell outside the medial aspect of the PFC were
not included in the study.
Histology
After the completion of behavioural testing, rats were
deeply anaesthetized with sodium pentobarbital and
were perfused transcardiacally with physiological
saline, followed by 4% paraformaldehyde. Brains
were removed from the skull and ﬁxed by immersion
in 4% paraformaldehyde overnight at 4 xC. Tissues
were washed and stored in 15–30% sucrose in PBS
at 4 xC, and stored at x70 xC before being sectioned
in the coronal or sagittal plane at 50 mm thickness
with a cryostat. Sections were mounted and stained
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with haematoxylin-eosin for histological examination.
Veriﬁcation of prefrontal electrolytic lesion or cortical
transection was done using the atlas of Paxinos and
Watson (2005) using a Nikon E800 microscope. Digital
images were captured using a Nikon Coolpix E995
camera attached to a stereoscopic zoom microscope
(Nikon SMZ800) equipped with a plan 1r lens.
Data analysis
Data are given as mean¡standard error of the mean
(S.E.M.) and were analysed by one- or two-way analysis
of variance (ANOVA) for independent or repeated
measures followed by post-hoc Newman–Keuls
multiple comparison test. Statistical signiﬁcance was
set at p<0.05.
Results
Characterization of MK-801-induced behaviours
The i.p. administration of 0.1 and 0.2 mg/kg MK-801
induced a dose-dependent and signiﬁcant increase
of locomotor activity. Two-way repeated-measures
ANOVA revealed a signiﬁcant eﬀect of group
(F2,20=21.1, p<0.00001), time (F2,40=31.3, p<
0.000001) and time group interaction (F4,40=6.1,
p<0.001) (Figure 3a). Post-hoc analysis revealed
signiﬁcant diﬀerences between saline and 0.2 mg/kg
MK-801, and between both MK-801 doses. The dose
of 0.1 mg/kg MK-801 was not signiﬁcantly diﬀerent
from saline. However, both doses of MK-801 induced
a marked reduction of the number of rearings (to 40%
of basal values) during the exploratory phase (ﬁrst
5 min) (Figure 3b). One-way ANOVA showed a
signiﬁcant eﬀect of the dose on rearings (F2,30=16.4,
p<0.0001). Post-hoc analysis revealed signiﬁcant
diﬀerences between both groups of MK-801-treated
rats and control rats, with no diﬀerences between the
MK-801 doses (Figure 3b).
Table 1 shows the pattern of motor activity (dis-
organized movements and ataxia signs) and stereo-
typies induced by MK-801. One-way ANOVA showed
that MK-801 induced a dose-dependent and signiﬁ-
cant eﬀect, increasing locomotor activity and dis-
organized movements (F2,30=12.8, p<0.0001) and the
number of fallings during movement (F2,30=5.32,
(a) (b)
(c) (d)
Cg
Cg
PrL
PrL
IL
IL
Figure 2. Localization of prefrontal cortex (PFC) lesions. (a) Black symbols ($) show the positions of the tip of the electrode used
to produce the electrolytic lesions. Current was passed at six positions per hemisphere (two descents, three points per descent).
Sections are taken from Paxinos and Watson (2005) (see Methods section for experimental details). (b) Shows a sagittal section
stained with haematoxylin-eosin showing the actual level of cortical transection. (c, d) Haematoxylin-eosin-stained sections
corresponding to (c) a sham-operated rat and (d) a rat subjected to electrolytic lesions. Note that the damage is restricted to the
medial aspect of the PFC. Bar size : (b) 2.5 mm; (c, d) 1 mm.
522 M. C. Scorza et al.
p<0.01) in the overall observation period (15 min).
The number of head shakes (F2,30=0.36, p<0.05) and
head weavings (F2,30=3.11, p<0.06) was not signiﬁ-
cantly aﬀected.
Eﬀect of PFC lesions on MK-801-induced behaviour
Figure 2 shows a schematic representation of the
location of PFC lesions and the actual PFC damage
induced by the electrolytic lesions (coronal sections)
and by the cortical transection (sagittal section). On the
basis of the above experiments, we choose the dose
of 0.2 mg/kg to examine the involvement of the
mPFC on the behavioural actions of MK-801. MK-801
eﬀects are given for the total examination period
(0–15 min) because the eﬀect on locomotor activity is
similar in the exploratory (0–5 min) and habituation
phases (5–15 min).
To analyse the eﬀect of the PFC electrolytic lesion
on the behavioural syndrome induced by MK-801
we performed a two-way ANOVA of the data corre-
sponding to sham and lesioned rats treated with
vehicle and MK-801. For locomotor activity, two-way
ANOVA revealed a signiﬁcant eﬀect of the treatment
(F1,26=104.1, p<0.0001), a trend for the lesion (F1,26=
3.28, p=0.08) and a non-signiﬁcant treatmentrlesion
interaction (F1,26=1.95, p=0.17). Post-hoc analysis
revealed signiﬁcant diﬀerences between vehicle
and MK-801 groups (Figure 4a). MK-801 induced a
signiﬁcant increase in locomotor activity, which was
diﬀerent from that of vehicle in both sham (p<0.0001)
and lesioned rats (p<0.0001). Consistent with the
marginal, yet non-signiﬁcant eﬀect of the lesion, there
was a slight reduction (p<0.05) of locomotor activity
in lesioned animals compared with sham animals
0
0
***
***
***
++ +++
+++
Time (min)
B
ea
m
 c
ro
ss
es
0
** **
R
ea
ri
n
g
s
(a)
(b)
1200
1000
800
600
400
200
5 10 15
50
40
30
20
10
Figure 3. Eﬀect of 0.1 and 0.2 mg/kgMK-801 on (a) locomotor
activity and (b) rearing behaviour. Values represent
mean¡S.E.M. of beam crosses at 5, 10 and 15 min and of the
ﬁrst 5 min of rearings. Controls were injected with
vehicle+saline. * Denotes statistical diﬀerences between
saline and MK-801 ; + denotes statistical diﬀerences between
MK-801 doses (***,+++ p<0.001, **,++ p<0.01 ; n=10–11
animals per group). (a)#, Control group; m, 0.1 mg/kg
MK-801 ;&, 0.2 mg/kg MK-801. (b)%, Control group;
, 0.1 mg/kg MK-801 ;&, 0.2 mg/kg MK-801.
Table 1. Pattern of motor activity and stereotypies induced by systemic adminis-
tration of MK-801
Treatment
Pattern of motor activity
Stereotypies
Disorganized
movement (0–3)
Ataxia signs
(number
of fallings)
Head
shakes
Head
weavings
Saline 0 0 2.5¡0.9 0
MK-801 (0.1 mg/kg) 1.5¡0.4** 1.4¡0.4* 3.9¡1.5 0.8¡0.4
MK-801 (0.2 mg/kg) 2.5¡0.3*** 1.7¡0.5* 3.2¡0.8 5.9¡3.1
Data are mean¡S.E.M.
* p<0.05, ** p<0.01, *** p<0.001 vs. controls (one-way ANOVA followed by
Newman–Keuls test) (n=10–11 animals per group).
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(2211¡292 vs. 2804¡160 beam crosses in 15 min,
respectively ; Figure 4a).
We also examined the eﬀect of MK-801 on rearings
during the initial 5 min, as performed in naive animals
(see above) as well as the impact of the mPFC lesion.
Two-way ANOVA revealed a signiﬁcant eﬀect of
treatment (F1,26=30.7, p<0.0001) a trend for the lesion
(F1,26=4.5, p=0.06) and non-signiﬁcant eﬀect of the
treatmentrlesion interaction (F1,26=2.88, p=0.10).
Post-hoc test revealed a signiﬁcant diﬀerence between
vehicle- and MK-801-treated rats in both sham
(p<0.0001) and lesioned groups (p<0.05) as well as a
signiﬁcant diﬀerence between the vehicle group in
sham and lesioned groups (p<0.05) (Figure 4b).
We calculated the reduction in locomotor activity
between 0–5 and 10–15 min (expressed as individual
percentages) as a measure of the animal’s adaptation
to the novel environment. Figure 4c shows the fall
in locomotor activity in control rats together with
the relative stability of locomotor activity in MK-
801-treated rats in both sham-operated and lesioned
rats. Two-way ANOVA revealed a signiﬁcant eﬀect
of treatment (F1,26=81.4, p<0.00001) a trend for the
lesion (F1,26=0.07, n.s.) and a non-signiﬁcant inter-
action between both factors (F1,26=1.2, n.s.).
We subsequently performed cortical transections
to produce a greater degree of prefrontal lesion in
order to examine the possible dependence of MK-
801 eﬀects on PFC activity. For locomotor activity,
two-way ANOVA showed a signiﬁcant eﬀect of treat-
ment (F1,23=104.35, p<0.00001) together with a non-
signiﬁcant eﬀect of lesion (F1,23=0.25, n.s.) but not
the interaction between both factors (F1,23=0.05, n.s.).
Post-hoc test revealed that MK-801 induced a signiﬁ-
cant increase in the locomotor activity compared with
the control group (p<0.0001) (Figure 5a), whereas
a signiﬁcant decrease in rearing behaviour was ob-
served with MK-801 (p<0.01) (Figure 5b).
Clz antagonism of MK-801 eﬀect : inﬂuence of the
mPFC electrolytic lesion
Figure 6 shows the total locomotor activity (0–15 min)
in sham and lesioned rats treated with vehicle,
0.2 mg/kg MK-801 and 1 mg/kg Clz+0.2 mg/kg
MK-801. In addition to examining the overall eﬀect
of Clz on MK-801 eﬀects, in this experiment we
also tested whether the eﬀect of Clz was dependent
on mPFC integrity. The rationale to perform these
experiments is based on recent data showing that Clz
reversed the hyperactivity of PFC neurons induced by
the NMDA receptor antagonist MK-801 (Homayoun
and Moghaddam, 2007b; Kargieman et al., 2007). We
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Figure 4. Eﬀect of 0.2 mg/kg MK-801 on (a) locomotor
activity and (b) rearings on control (sham-operated) rats
and in rats subjected to electrolytic lesions. Controls were
injected with vehicle+saline. (c) Shows the change in
locomotor activity in sham and lesioned rats treated with
saline or 0.2 mg/kg MK-801. Note the marked reduction
in locomotor activity in control rats together with the
persistence in MK-801-treated rats. (a) Beam crosses
(mean¡S.E.M.) in 15 min ; (b) the number of rearings in the
ﬁrst 5 min ; (c) the percentage reduction of the basal
locomotor activity in each group (mean¡S.E.M.). * Denotes
statistical diﬀerences between saline and MK-801 in both
experimental groups (sham and lesioned) ; # denotes
signiﬁcant diﬀerences between vehicle+MK-801 group of
sham vs. lesioned animals (*** p<0.001, *, # p<0.05 ; n=6–8
animals per group). All panels :%, control group;&,
0.2 mg/kg MK-801.
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therefore explored the possibility of a PFC-mediated
action of Clz to reverse MK-801-induced hyper-
activity. A dose of 1 mg/kg Clz was selected because
it was found to blockade the behavioural syndrome
produced by MK-801 without aﬀecting per se
the animal’s behaviour (data not shown).
To examine the dependence of Clz reversal of the
MK-801-induced eﬀect on PFC integrity we performed
two-way ANOVA of the data of sham and lesioned
animals treated with MK-801 alone or in combination
with Clz. Two-way ANOVA of all experimental
groups (vehicle, MK-801 alone, Clz+MK-801, both
sham and lesioned) revealed a signiﬁcant eﬀect of
treatment (F2,40=46.7, p<0.0001) a marginally signiﬁ-
cant eﬀect of lesion (F1,40=3.66, p=0.06) and a non-
signiﬁcant treatmentrlesion interaction (F2,40=0.93,
p=0.39). Post-hoc tests revealed signiﬁcant diﬀerences
between MK-801 and vehicle in sham and lesioned
rats, betweenMK-801 alone and Clz+MK-801 in sham
and lesioned rats, and between the MK-801 group
in sham and lesioned rats (Figure 6a). Clz (1 mg/kg)
was eﬀective in blockading the hyperactivity induced
by MK-801 without any eﬀect per se on the basal
locomotor activity (data not shown). Moreover, we
observed that Clz failed to blockade the decrease in
rearing behaviour induced by MK-801 in both sham
and lesioned animals (Figure 6b).
Table 2 shows the antagonizing eﬀect of Clz on
MK-801-induced signs of uncoordinated motor
activity, ataxia signs and stereotypies in sham and
PFC-lesioned rats. Two-way ANOVA of the data re-
vealed (1) a signiﬁcant eﬀect of treatment (F2,40=10.46,
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Figure 6. Involvement of the medial prefrontal cortex in the
eﬀect of 0.2 mg/kg MK-801 and clozapine- (Clz, 1 mg/kg)
induced reversal of MK-801-induced (a) hyperlocomotion
and (b) rearing behaviour. Values are mean¡S.E.M. of beam
crosses in 15 min and rearings recorded in the ﬁrst 5 min
respectively. Controls were treated with vehicle+saline.
* Denotes signiﬁcant diﬀerences between controls and
vehicle+MK-801 group; + denotes signiﬁcant diﬀerences
between vehicle+MK-801 and Clz+MK-801 ; # denotes
signiﬁcant diﬀerences between vehicle+MK-801 group of
sham vs. lesioned animals (***,+++ p<0.001 ; **,++ p<0.01 ;
*, # p<0.05 ; n=6–8 animals per group). Both panels :%,
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Clz+0.2 mg/kg MK-801.
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Figure 5. Eﬀect of 0.2 mg/kg MK-801 on (a) locomotor
activity and (b) rearings in cortically transected rats
compared with sham-operated rats. Values are mean¡S.E.M.
of beam crosses in 15 min and rearings were scored on the
ﬁrst 5 min. Control group are the sham-operated rats injected
with vehicle+saline. * Denotes statistical diﬀerences between
control group and MK-801 (*** p<0.001, ** p<0.01, * p<0.05 ;
n=6–8 animals per group). Both panels :%, control group;
, 0.2 mg/kg MK-801 of sham-operated rats ;&, 0.2 mg/kg
MK-801 of cortically transected rats.
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p<0.0002), a non-signiﬁcant eﬀect of lesion or treat-
mentrlesion interaction for head weavings ; (2) a sig-
niﬁcant eﬀect of treatment (F2,40=39.66, p<0.0001) and
lesion (F1,40=7.37, p<0.01) but not of the interaction
for disorganized movement ; (3) a signiﬁcant eﬀect of
treatment (F2,40=8.46, p<0.001) and a non-signiﬁcant
of lesion or interaction for the number of falls, and (4) a
trend for treatment (F2,40=2.63, p=0.08), non-signiﬁ-
cant eﬀect for lesion (F1,40=1.37, p<0.25) and signiﬁ-
cant eﬀect of treatmentrlesion interaction (F2,40=4.67,
p<0.05) for the head shakes. Post-hoc analysis re-
vealed that MK-801 produced an overall increase in
these behaviours that was reversed by Clz in both
groups of animals.
Discussion
The present study further characterized the motor
behavioural syndrome induced by MK-801 in rats
and speciﬁcally examined whether these eﬀects de-
pend on the cellular integrity of the PFC. Moreover,
we examined whether the ability of the atypical
antipsychotic Clz to reverse MK-801-induced behav-
ioural signs depends also on PFC integrity. Rearings
pre-treatment were markedly aﬀected by an electro-
lytic lesion, which produced only a slight (21%)
attenuation of the locomotor activity induced by
MK-801 whereas cortical transection did not aﬀect it.
Overall, this suggests that the motor syndrome
induced by MK-801 and its antagonism by Clz is
mainly driven by blockade of NMDA receptors out-
side the PFC.
Characterization of MK-801-induced behaviour
The main eﬀects induced by MK-801 are in agreement
with previous literature (Andine et al., 1999 ; Deustch
et al., 1997 ; Geyer and Ellenbroek, 2003 ; Leriche et al.,
2003 ; Wu et al., 2005). MK-801 induced a behavioural
syndrome characterized by hyperlocomotion with
disorganized movements (e.g. not guided by normal
exploration), slight ataxia signs, stereotypical behav-
iours, such as head weavings, and a marked sup-
pression of rearings. Although hyperlocomotion has
been extensively examined by previous reports, the
eﬀect of NMDA receptor blockade on rearings and
other behaviours has received comparatively little
attention (O¨gren et al., 1994, Wu et al., 2005).
Rearings are a component of the natural exploratory
behaviour directly related to the environment novelty
(Bardo et al., 1990 ; Fink and Smith, 1980 ; Geyer et al.,
1986). Thus, untreated rats placed in the unfamiliar
OF showed a greater score than MK-801-treated rats
in rearing behaviour during the ﬁrst 5 min, corres-
ponding to the exploratory phase. This reduction in
rearings was associated with an increase in hori-
zontal locomotor activity. The lower dose of MK-801
(0.1 mg/kg), which did not evoke hyperlocomotion
evoked a similar reduction in rearings, suggesting
two independent eﬀects of MK-801. Actually, MK-801
Table 2. Eﬀect of clozapine on the pattern of motor activity and stereotypies induced
by MK-801 in sham-operated and lesioned rats
Treatment
Pattern of motor activity
Stereotypies
Disorganized
movement (0–3)
Ataxia signs
(number of
fallings)
Head
shakes
Head
weavings
Vehicle+saline (S) 0 0 1.7¡0.6 0
Vehicle+MK-801 (S) 2.7¡0.1*** 7.1¡2.9** 3.0¡0.9 16.6¡4.6***
Clz+MK-801 (S) 1.1¡0.4**+++ 0.9¡0.4*+ 0.12¡0.1+ 4.5¡2.9++
Vehicle+saline (L) 0 0 1.6¡0.7 0
Vehicle+MK-801 (L) 2.0¡0.4*** 5.1¡2.4* 0.4¡0.2 7.8¡3.6*
Clz+MK-801 (L) 0.12¡0.1+++ 0.5¡0.2+ 0.8¡0.5 0.25¡0.1+
S, sham-operated rats ; L, lesioned rats.
Data are mean¡S.E.M.
* Denotes the signiﬁcant diﬀerences between controls and drug-treated rats ;
+ denotes the statistical diﬀerences between vehicle+MK-801 and Clz+MK-801.
Two-way ANOVA followed by post-hoc Newman Keuls test : *,+ p<0.05 ;
**,++ p<0.01 ; ***,+++ p<0.001 (n=6–8 animals per group).
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reduced regains to the same extent in habituated and
non-habituated animals (M. C. Scorza, unpublished
observations), which indicates that MK-801 alters
the adaptation to novel environments independently
of previous experience.
The opposite eﬀects of MK-801 on rearings and
locomotor activity are discordant with those of
amphetamine, which concurrently increases motor
activity and rearings (Kelly et al., 1975 ; Mele et al.,
1998 ; Pesˇic et al., 2003 ; M. C. Scorza, unpublished
observations). This further suggests that rearing
suppression by MK-801 is not secondary to increased
locomotor activity. Further, ataxia induced by NMDA
receptor blockade does not seem to be involved in the
suppression of rearings since, as seen with MK-801,
phencyclidine (5 mg/kg i.p.) increased locomotor
activity and decreased rearings but did not induce
ataxia (M. C. Scorza et al., unpublished observations).
Interestingly, both the selective electrolytic lesion
of the mPFC and the more widespread lesion induced
by cortical transection reduced rearings without
aﬀecting basal locomotor activity. Rearing behaviour
has been generally associated with subcortical dopa-
mine activation (Bardo et al., 1990 ; Clarke et al., 1988 ;
Fink and Smith, 1980). Our results indicate that
glutamatergic transmission in the PFC is also very
important for the expression of this behaviour. Indeed,
dopaminergic and GABAergic neurons of the meso-
limbic system are innervated and controlled, directly
or indirectly, by descending glutamatergic aﬀerents
from the mPFC (Bortolozzi et al., 2005 ; Carr and
Sesack, 2000; Dı´az-Mataix et al., 2005; Sesack and
Pickel, 1992 ; Taber and Fibiger, 1995). Cortical trans-
ection, as performed herein, fully suppressed burst
activity in dopaminergic neurons of the ventral
tegmental area (Dı´az-Mataix et al., 2005). Thus, it is
possible that removal of excitatory inputs from the
PFC prevents the rise in dopaminergic activity that
assigns salience to novel environmental stimuli
(Schultz, 1997), thus, decreasing this component of
exploratory behaviour.
Ataxia and motor uncoordination induced by
MK-801 may perhaps be accounted for the blockade
of certain NMDA receptor subunits (NMDAR2C and/
or NMDAR2D, which are expressed in granule cells in
the cerebellum (Pizzi et al., 1999) and bind [3H]MK-801
(Nakanishi, 1992). Indeed, the alteration of GABAergic
transmission in this structure evokes ataxia signs in
mice (Chiu et al., 2005).
MK-801 caused increased head weavings without
altering head shakes. The latter is natural behaviour
that can be enhanced by the administration of sero-
tonergic agents targeting 5-HT2 receptors (Glennon
and Lucki, 1989). However, lateral head weaving is
a pharmacologically induced stereotypy which is
present, for instance, in the serotonergic syndrome
induced by 5-HT1A agonists (Tricklebank et al., 1984).
In this regard, previous studies have shown that
the stereotypic behaviour induced by MK-801 can be
blockaded by selective 5-HT1A receptor antagonists
(Lo¨scher and Ho¨nack, 1993), an eﬀect perhaps
accounted for by the serotonin increase observed in
microdialysis studies (Lo´pez-Gil et al., 2007).
Eﬀect of PFC lesions on MK-801-induced behaviour
Phencyclidine and MK-801 produce a marked dis-
ruption of the neuronal activity in the mPFC, with
an overall increase in discharge rate, although some
neuronal populations are inhibited (Homayoun and
Moghaddam, 2007b; Jackson et al., 2004 ; Kargieman
et al., 2007 ; Suzuki et al., 2002). The increased pyr-
amidal neuron activity in the PFC may involve
NDMA receptor blockade on local (Homayoun and
Moghaddam, 2007b) or distal elements projecting to
the PFC (Kargieman et al., 2007). Thus, blockade of
NMDA receptor-mediated tonic glutamatergic inputs
onto local GABAergic interneurons and/or GABA-
controlled excitatory aﬀerents to the PFC would result
in pyramidal cell disinhibition (Krystal et al., 2003 ;
Tsai and Coyle, 2002). In support of the latter possi-
bility is the fact that local blockade of NMDA receptors
did not increase neuronal activity in the mPFC, yet
blockade in the CA1/subiculum, an aﬀerent area to
the mPFC, increased the activity of mPFC neurons
( Jodo et al., 2005; Suzuki et al., 2002). Moreover, un-
like systemic administration, the local application of
ketamine and phencyclidine did not increase sero-
tonin release in the mPFC (Amargo´s-Bosch et al.,
2006). Similarly, systemic administration, but not local
application in the mPFC of MK-801 increased sero-
tonin and glutamate output in the mPFC (Lo´pez-Gil
et al., 2007). However, systemic MK-801 adminis-
tration reduced ﬁring rate of fast-spiking interneurons
in the mPFC (Homayoun and Moghaddam, 2007b).
The main working hypothesis of the present
study is that the increased PFC activity (secondary to
the eﬀect of MK-801 in other brain areas) may drive,
via descending excitatory aﬀerents, an increase in the
activity of cortical and subcortical motor areas which
would result in the MK-801-induced hyperlocomo-
tion. Overall, the PFC has been implicated in cognitive
change (Verma and Moghaddam, 1996) and the regu-
lation of the sensoriomotor gating deﬁcit (Schwabe
and Koch, 2004) induced by NMDA receptor antag-
onists. This is in agreement with the role of PFC in
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higher brain functions, such as working memory,
action planning and behavioural inhibition (Fuster,
1997 ; Goldman-Rakic, 1996 ; Miller and Cohen, 2001).
However, other studies suggest the participation of
the PFC in the hyperactivity and stereotypies induced
by NMDA antagonist (Feenstra et al., 2002 ; Jentsch
et al., 1998; Takahata and Moghaddam, 2003). The
present data do not support this view completely. On
the contrary, it appears that the behavioural syndrome
induced by MK-801 is mainly independent of PFC
inputs onto motor areas, either cortical or subcortical.
One way to reconcile the present observations with
the eﬀects of NMDA receptor antagonists in rat and
human PFC (Breier et al., 1997 ; Jackson et al., 2004;
Kargieman et al., 2007; Suzuki et al., 2002) is that
NMDA receptor blockade in a distal brain area may
result in a concurrent subsequent alteration of gluta-
matergic neurotransmission in the PFC – which would
account for the cognitive and perceptual changes –
and in other structures involved in motor behaviour.
The hippocampus has been proposed to mediate the
increase in PFC neuronal activity via an activation of
hippocampus-prefrontal inputs (Jodo et al., 2005). The
hippocampus also projects, among other structures, to
the ventral striatum and may modulate information
ﬂow through basal ganglia circuits (Grace, 2000).
However, NMDA receptor blockade in other brain
structures may also account. Hence, MK-801 enhances
c-fos expression in various thalamic nuclei that pro-
ject to motor and association areas, including the
striatum and PFC (Vaisanen et al., 2004). Recent
studies using double in-situ hybridization show that
phencyclidine enhances c-fos in glutamatergic neurons
of various thalamic nuclei, including the mediodorsal
and centromedial nuclei, which project densely to the
PFC, but not in GABAergic neurons of the reticular
nucleus of the thalamus, which inhibits the rest of
thalamic nuclei (Kargieman et al., 2007). Thus, NMDA
receptor antagonists might inhibit tonic NMDA inputs
onto GABAergic neurons of the reticular nucleus, an
eﬀect that would then disinhibit several thalamic
projections to association and motor areas, resulting
in the array of diﬀerent pharmacological eﬀects pro-
duced by these agents.
Clz antagonism of MK-801 eﬀect : the eﬀect of the
mPFC lesion
The behavioural syndrome produced by NMDA
antagonists has been widely used as an animal model
to study the mechanism of action of conventional
and atypical antipsychotics (Geyer and Ellenbroek,
2003). Classical neuroleptics modulate excitatory
inputs onto limbic striatum following the blockade
of dopamine D2 receptors. However, several studies
indicate that atypical antipsychotics have prominent
actions in the PFC. First, Clz displays lower aﬃnity for
D2 than for 5-HT2A receptors (Meltzer, 1999) which are
expressed by a very large proportion of PFC neurons
(Amargo´s-Bosch et al., 2004 ; Santana et al., 2004).
Second, 5-HT2A receptor antagonism contributes sub-
stantially to the ability of atypical antipsychotics to
attenuate this behavioural eﬀect of NMDA antagonists
(Gleason and Shannon, 1997). Third, Clz acts on PFC
5-HT1A receptors to modulate the local dopamine
release, an eﬀect potentially involved in the pro-
cognitive actions of Clz, by a local action (Dı´az-Mataix
et al., 2005). Finally, Clz reverses the increase in
glutamatergic transmission in the PFC, as assessed
in neurochemical and electrophysiological studies
(Homayoun and Moghaddam, 2007b; Kargieman et
al., 2007 ; Lo´pez-Gil et al., 2007). Overall, these results
suggest that the reversal by Clz of the motor syndrome
induced by MK-801 might require the anatomical and
functional integrity of the PFC. However, contrary to
these expectations, the present data indicate that
Clz antagonized the MK-801-induced hyperlocomo-
tion equally in sham and lesioned rats.
Since the behavioural repertoire induced by MK-
801 and the antagonism by Clz seems to be mostly
mediated by pathways involving motor structures,
it seems reasonable to assume that Clz may act at
once in various brain structures. Thus, in addition to
serotonin receptors in the mPFC, it may target such
receptors in other cortical or subcortical areas, which
also show a high abundance of 5-HT1A and 5-HT2A/2C
receptors (Pompeiano et al. 1992, 1994). At the dose
used, Clz occupies a minor proportion of dopamine
D2 receptors (y10%, Schotte et al., 1993), which
suggests that dopaminergic blockade is not involved
in the antagonism of MK-801-induced hyperlocomo-
tion. An alternative mechanism is the blockade of
a1-adrenoceptors, for which Clz shows high in-vitro
aﬃnity (Arnt and Skarsfeldt, 1998 ; Bymaster et al.,
1996). In this regard, it was found that prazozin, an
a1-adrenoceptor antagonist reduces MK-801-induced
hyperlocomotion and stereotypies (Harkin et al.,
2001). Interestingly, the decrease in rearings elicited by
MK-801 was not antagonized by Clz, indicating once
again that the NMDA receptors involved in the
regulation of locomotor and rearing behaviour act
via diﬀerent pathways. Indeed, the present results
support the view that the PFC plays a minor role in
hyperlocomotion evoked by MK-801, but they do not
exclude at all the involvement of this cortical area
in the cognitive changes evoked by NMDA receptor
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blockade, which occurs at MK-801 doses lower than
those increasing locomotor activity (Jackson et al.,
2004).
Further work is needed to clarify what speciﬁc brain
regions are involved in the behavioural syndrome
induced by NMDA receptor antagonists and the
mechanism of action of atypical antipsychotics to
reverse these eﬀects.
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